IBRN · ARCA · ETF
iShares Neuroscience and Healthcare ETF (IBRN) Price, Holdings & Fees
iShares Neuroscience and Healthcare ETF (IBRN) closed at $636.99 on Oct 9, 2026, down 0.68% from the previous close of $641.38.
Share price, past year
1Y +1.73%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $636.99 |
| Sep 30, 2026 | $650.60 |
| Aug 31, 2026 | $616.02 |
| Jul 31, 2026 | $619.02 |
| Jun 30, 2026 | $612.27 |
| May 29, 2026 | $609.27 |
| Apr 30, 2026 | $639.36 |
| Mar 31, 2026 | $650.21 |
| Feb 27, 2026 | $670.84 |
| Jan 30, 2026 | $670.86 |
| Dec 31, 2025 | $671.03 |
| Nov 28, 2025 | $669.20 |
| Oct 31, 2025 | $619.27 |
Key statistics
- Expense ratio
- 0.47%
- as of Jul 31, 2025
- Net assets
- $5.5M
- as of Jul 31, 2026
- Holdings
- 78
- as of Jul 31, 2026
- 52-week range
- $592.01 – $695.81
iShares Neuroscience and Healthcare ETF's expense ratio is 0.47%: $47.00 a year on $10,000 invested.
Holdings
iShares Neuroscience and Healthcare ETF held 78 investments worth $5.49M as of Jul 31, 2026. Its largest holding was BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares, at 14.64% of the fund.
| # | Holding | % of fund | Value |
|---|---|---|---|
| 1 | BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares | 14.64% | $802.95K |
| 2 | Dianthus Therapeutics Inc | 5.34% | $292.85K |
| 3 | Xenon Pharmaceuticals Inc | 4.87% | $267.22K |
| 4 | Praxis Precision Medicines Inc | 4.87% | $267.20K |
| 5 | ACADIA PHARMACEUTICALS INC. | 4.69% | $257.38K |
| 6 | ARROWHEAD PHARMACEUTICALS, INC. | 4.65% | $255.30K |
| 7 | ALKERMES PUBLIC LIMITED COMPANY | 4.60% | $252.45K |
| 8 | Scholar Rock Holding Corp | 4.29% | $235.48K |
| 9 | BIOGEN INC. | 4.18% | $229.13K |
| 10 | NEUROCRINE BIOSCIENCES, INC. | 4.09% | $224.35K |
| 11 | argenx SE | 3.86% | $211.75K |
| 12 | PTC THERAPEUTICS, INC. | 3.85% | $211.44K |
| 13 | AXSOME THERAPEUTICS, INC. | 3.77% | $206.87K |
| 14 | Denali Therapeutics Inc | 3.67% | $201.43K |
| 15 | Dyne Therapeutics, Inc | 3.56% | $195.50K |
| 16 | Edgewise Therapeutics Inc | 3.23% | $177.35K |
| 17 | SUPERNUS PHARMACEUTICALS, INC. | 2.61% | $142.91K |
| 18 | AxoGen, Inc. | 2.34% | $128.36K |
| 19 | SK Biopharmaceuticals Co Ltd | 2.30% | $126.09K |
| 20 | H. LUNDBECK A/S | 1.84% | $100.79K |
| 21 | Biohaven Ltd | 1.82% | $99.59K |
| 22 | SAREPTA THERAPEUTICS, INC. | 1.61% | $88.48K |
| 23 | BioArctic AB | 1.56% | $85.56K |
| 24 | Taysha Gene Therapies Inc | 1.50% | $82.03K |
| 25 | Neuren Pharmaceuticals Ltd | 1.48% | $81.11K |
Top 25 of 78 holdings, as of Jul 31, 2026. Percentages are of the fund's net assets.
What the fund owns
| Asset type | % of fund |
|---|---|
| Stocks | 95.51% |
| Cash and short-term investments | 14.75% |
| Other | 4.38% |
| Country | % of fund |
|---|---|
| United States | 85.16% |
| Canada | 5.47% |
| Ireland | 5.01% |
| Netherlands | 3.86% |
| South Korea | 2.42% |
| Sweden | 2.36% |
| Denmark | 1.84% |
| Switzerland | 1.84% |
| British Virgin Islands | 1.82% |
| New Zealand | 1.48% |
Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.
Monthly total returns
Over the 3 months to Jul 31, 2026, iShares Neuroscience and Healthcare ETF's total return was +6.01%, as reported to the SEC.
| Month | Total return |
|---|---|
| Jul 31, 2026 | −6.00% |
| Jun 30, 2026 | +8.47% |
| May 31, 2026 | +3.97% |
The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.
Fund profile
- Name
- iShares Neuroscience and Healthcare ETF
- Ticker
- IBRN
- Exchange
- ARCA
- Fund type
- ETF
- Trust
- iSHARES TRUST
- SEC series ID
- S000076483
- SEC CIK
- 0001100663
- Fractional shares
- No
Recent SEC filings
- Sep 23, 2026
- Oct 5, 2026
- 485BPOSProspectus updateSep 14, 2026
- 485BPOSProspectus updateAug 21, 2026
- 485BPOSProspectus updateJul 27, 2026
- 485BPOSProspectus updateJul 7, 2026
- Jul 2, 2026
- Jul 2, 2026
Shareholder reports and prospectuses are filed by iSHARES TRUST, the trust behind iShares Neuroscience and Healthcare ETF, and cover all of its funds.
Frequently asked questions
What is IBRN's price?
iShares Neuroscience and Healthcare ETF (IBRN) closed at $636.99 on Oct 9, 2026, down 0.68% from the previous close of $641.38.
What is IBRN's expense ratio?
iShares Neuroscience and Healthcare ETF's expense ratio is 0.47%: $47.00 a year on $10,000 invested.
What does IBRN hold?
iShares Neuroscience and Healthcare ETF held 78 investments worth $5.49M as of Jul 31, 2026. Its largest holding was BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares, at 14.64% of the fund. Its five largest holdings were BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares, Dianthus Therapeutics Inc, Xenon Pharmaceuticals Inc, Praxis Precision Medicines Inc, ACADIA PHARMACEUTICALS INC..
How has IBRN performed?
Over the 3 months to Jul 31, 2026, iShares Neuroscience and Healthcare ETF's total return was +6.01%, as reported to the SEC.
Sources and methodology
Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jul 31, 2026 (filed Sep 23, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Jul 31, 2025. Prices are generated sample data for development. Data sources and disclosures